Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)-
CDKL5 Deficiency Disorder
Zogenix, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CDKL5 Deficiency Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganaxolone Marinus Pharmaceuticals | Phase 3 | B |
Soticlestat Takeda | Phase 2 | CCC |
Same molecule, other indications
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →